Enanta Pharmaceuticals Inc (ENTA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Enanta Pharmaceuticals Inc (ENTA) has a cash flow conversion efficiency ratio of -0.099x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.97 Million) by net assets ($101.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Enanta Pharmaceuticals Inc for the company's overall valuation and market capitalisation.
Enanta Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Enanta Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Enanta Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Enanta Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore earnings quality score of Enanta Pharmaceuticals Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tesco PLC
LSE:TSCO
|
0.152x |
|
D-Link Corp
TW:2332
|
-0.022x |
|
Integrated Service Technology
TWO:3289
|
0.036x |
|
Xinxiang Tianli Energy Co. Ltd. A
SHE:301152
|
0.063x |
|
Oxiquim S.A
SN:OXIQUIM
|
0.051x |
|
Hellenic Exchanges - Athens Stock Exchange SA
AT:EXAE
|
0.162x |
|
Jahwa Electron
KO:033240
|
0.032x |
|
Nanjing Wondux Environmental Protection Technology Corp Ltd
SHG:688178
|
-0.035x |
Annual Cash Flow Conversion Efficiency for Enanta Pharmaceuticals Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Enanta Pharmaceuticals Inc from 2011 to 2025. View ENTA stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $64.72 Million | $-19.27 Million | -0.298x | +51.30% |
| 2024-09-30 | $128.81 Million | $-78.76 Million | -0.611x | -28.47% |
| 2023-09-30 | $216.74 Million | $-103.15 Million | -0.476x | -80.39% |
| 2022-09-30 | $321.33 Million | $-84.78 Million | -0.264x | -50.56% |
| 2021-09-30 | $399.43 Million | $-70.00 Million | -0.175x | -1226.35% |
| 2020-09-30 | $455.58 Million | $7.09 Million | 0.016x | -89.92% |
| 2019-09-30 | $462.49 Million | $71.42 Million | 0.154x | +108.05% |
| 2018-09-30 | $393.68 Million | $29.22 Million | 0.074x | -57.47% |
| 2017-09-30 | $301.68 Million | $52.65 Million | 0.175x | +31.57% |
| 2016-09-30 | $269.94 Million | $35.81 Million | 0.133x | -59.14% |
| 2015-09-30 | $236.16 Million | $76.67 Million | 0.325x | +139.18% |
| 2014-09-30 | $148.65 Million | $20.18 Million | 0.136x | +40.76% |
| 2013-09-30 | $110.47 Million | $10.65 Million | 0.096x | -81.27% |
| 2012-09-30 | $43.93 Million | $22.62 Million | 0.515x | +382.94% |
| 2011-09-30 | $-131.96 Million | $24.02 Million | -0.182x | -- |
About Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respirato… Read more